CSIMarket


Fate Therapeutics Inc   (FATE)
Other Ticker:  
 


 

Fate Therapeutics Inc

FATE's Financial Statements and Analysis



Fate Therapeutics Inc narrowed third quarter of 2023 net loss per share of $-0.46 compare to net loss per share of $-0.86 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.54 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.46 $  2 Mill
$+0.40     $-13M     -87.02 %



Fate Therapeutics Inc 's Revenue fell by -87.02 % in third quarter of 2023 (Sep 30 2023) year on year, to $2 million and advanced by 108.36 % sequentially.


Fate Therapeutics Inc is

More on FATE's Income Statement



Fate Therapeutics Inc 's in thethird quarter of 2023 recorded net loss of $-45.170 million, an improvement compare to net loss of $-83.563 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-52.755 million realized in previous quarter.

More on FATE's Growth

Fate Therapeutics Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-13 million, capital expenditures grew by -8.676-93.49%, to $-1 millions compare to same quarter a year ago

More on FATE's Cash flow Statement


Fate Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Fate Therapeutics Inc payed $ -1.73 cash per share, on a free-cash flow basis .

Book value fell by -8.15 % sequentially to $4.09 per share, -20.59% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.09 per share from $ 4.45.

Company issued 0.17 million shares or 0.17 % in Sep 30 2023.


More on FATE's Dividends

 Market Capitalization (Millions) 676
 Shares Outstanding (Millions) 99
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 106
 Net Income (TTM) (Millions $) -173
 Cash Flow (TTM) (Millions $) -49
 Capital Exp. (TTM) (Millions $) -13
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 208




Fate Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Fate Therapeutics Inc had negative $ -1.73 cash flow per share, on a free-cash flow basis .

Book value fell by -8.15 % sequentially to $4.09 per share, -20.59% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 4.09 per share from $ 4.45.

Company issued 0.17 million shares or 0.17 % in Sep 30 2023.


More on FATE's Balance Sheets

 Market Capitalization (Millions) 676
 Shares Outstanding (Millions) 99
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 106
 Net Income (TTM) (Millions $) -173
 Cash Flow (TTM) (Millions $) -49
 Capital Exp. (TTM) (Millions $) -13
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 208
   


  News about Fate Therapeutics Inc Earnings

Fate Therapeutics Inc Witnesses Remarkable Vanishing Losses in Q3 of 2023, Setting a Promising Trend for Investors



Fate Therapeutics Inc, a leading biotechnology company, has experienced significant fluctuations in its stock performance over the past few trading days. While the recent increase of 38.15% is noteworthy, the shares have witnessed a decline of -76.5% year-to-date. Additionally, the company's stock is currently trading -65.4% below its 52-week average on the NASDAQ. To gain a better understanding of the outlook for Fate Therapeutics Inc, let's delve into its recent financial results and evaluate their potential impact on the company's future.
1. Improvement in Earnings:
During the July to September 2023 interval, Fate Therapeutics Inc achieved a significant improvement in earnings. Its loss ...

Challenging Second Quarter of 2023 Puts Fate Therapeutics Inc in a Serious Struggle

Over the course of the last five trading days, Fate Therapeut...

Fate Therapeutics Inc Achieves Impressive 220.3% Surge in Revenue for Fiscal Year Ending March 31, 2023

Fate Therapeutics Inc (FATE) is a clinical-stage biopharmaceutical company that focuses on developing cell-based therapeutics for the treatment of various diseases. The company's focus is on using induced pluripotent stem cell (iPSC)-derived cell therapies to develop treatments for cancer, immune disorders, and genetic disorders.
The company's innovative approach involves the use of iPSCs, which are essentially adult cells that have been reprogrammed to a pluripotent state, meaning they have the potential to differentiate into any type of cell in the body. This approach allows for the development of highly specific and targeted cell therapies, which can be designed to address specific disease pathways.

Date modified: 2023-11-10T01:06:15+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com